InsiderDB

Lobbying disclosures · Lobbying report

REGN: second_quarter 2026 lobbying report

Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space. Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers. Intellectual property legislation related to biopharmaceutical manufacturers. Trade and tariff issues related to corporations. Tax and inflation issues related to corporations.

Follow REGN
Became public
Jul 20, 2026, 8:34 PM EDT
Event / period date
Not stated
Collected
Nov 10, 2026, 3:58 PM EST

Why this is connected

Exact legal-name match: REGENERON PHARMACEUTICALS, INC. (https://www.sec.gov/Archives/edgar/data/872589/).

Reported lobbying amounts

Expenses: $630,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/e66ffb43-8909-414c-b4e4-bab42e2065e1/","filing_uuid":"e66ffb43-8909-414c-b4e4-bab42e2065e1","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/e66ffb43-8909-414c-b4e4-bab42e2065e1/print/","filing_document_content_type":"text/html","income":null,"expenses":"630000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Maya J. Bermingham","dt_posted":"2026-07-20T20:34:37-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"777 OLD SAW MILL RIVER ROAD","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"TARRYTOWN","registrant_state":"NY","registrant_zip":"10591","registrant":{"id":401104131,"url":"https://lda.gov/api/v1/registrants/401104131/","house_registrant_id":null,"name":"REGENERON PHARMACEUTICALS, INC","description":"Biopharmaceutical development and manufacturing","address_1":"777 OLD SAW MILL RIVER ROAD","address_2":null,"address_3":null,"address_4":null,"city":"TARRYTOWN","state":"NY","state_display":"New York","zip":"10591","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MAYA J. BERMINGHAM","contact_telephone":"+1 914-598-3031","dt_updated":"2026-07-29T09:39:25.971423-04:00"},"client":{"id":200807,"url":"https://lda.gov/api/v1/clients/200807/","client_id":12,"name":"REGENERON PHARMACEUTICALS, INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-08-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140574,"prefix":null,"prefix_display":null,"first_name":"MADDIE","nickname":null,"middle_name":null,"last_name":"DAVIDSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140575,"prefix":null,"prefix_display":null,"first_name":"EBEN","nickname":null,"middle_name":null,"last_name":"DUROSS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71871,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"HADDAD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71871,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"HADDAD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140574,"prefix":null,"prefix_display":null,"first_name":"MADDIE","nickname":null,"middle_name":null,"last_name":"DAVIDSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Intellectual property legislation related to biopharmaceutical manufacturers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140575,"prefix":null,"prefix_display":null,"first_name":"EBEN","nickname":null,"middle_name":null,"last_name":"DUROSS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140574,"prefix":null,"prefix_display":null,"first_name":"MADDIE","nickname":null,"middle_name":null,"last_name":"DAVIDSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71871,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"HADDAD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Trade and tariff issues related to corporations.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140574,"prefix":null,"prefix_display":null,"first_name":"MADDIE","nickname":null,"middle_name":null,"last_name":"DAVIDSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140575,"prefix":null,"prefix_display":null,"first_name":"EBEN","nickname":null,"middle_name":null,"last_name":"DUROSS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax and inflation issues related to corporations.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140575,"prefix":null,"prefix_display":null,"first_name":"EBEN","nickname":null,"middle_name":null,"last_name":"DUROSS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71871,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"HADDAD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140574,"prefix":null,"prefix_display":null,"first_name":"MADDIE","nickname":null,"middle_name":null,"last_name":"DAVIDSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Congressional trading in REGN

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.